Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

actavis pharma, inc. - betamethasone valerate (unii: 9ifa5xm7r2) (betamethasone - unii:9842x06q6m) - betamethasone valerate 1.2 mg in 1 g - topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

proficient rx lp - betamethasone valerate (unii: 9ifa5xm7r2) (betamethasone - unii:9842x06q6m) - betamethasone valerate 1.2 mg in 1 g - topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - betamethasone valerate (unii: 9ifa5xm7r2) (betamethasone - unii:9842x06q6m) - betamethasone valerate 1.2 mg in 1 g - topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

proficient rx lp - betamethasone valerate (unii: 9ifa5xm7r2) (betamethasone - unii:9842x06q6m) - betamethasone valerate 1.2 mg in 1 g - topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Malaysia - Englisch - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pharmaniaga manufacturing berhad - neomycin sulphate; betamethasone-17 valerate -

Malaysia - Englisch - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

hoe pharmaceuticals sdn. bhd. - neomycin sulphate; betamethasone valerate -

Malaysia - Englisch - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

hoe pharmaceuticals sdn. bhd. - betamethasone valerate; neomycin sulphate -

Kenia - Englisch - Pharmacy and Poisons Board

shelys pharmaceuticals limited plote no. 696, new bagamoyo road, mwenge. p. o. - betamethasone dipropionate bp, neomycin sulphate… - cream - betamethasone dipropionate bp 0.064%w/w, neomycin… - combinations of moderately potent corticosteroids

Kenia - Englisch - Pharmacy and Poisons Board

laboratory & allied ltd p.o box 42875 gpo 00100 nairobi, kenya - betamethasone sodium phosphate neomycin sulphate… - ear/eye drops, solution - betamethasone sodium phosphate bp 0.1 % w/v … - otological anti-infectives

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - betamethasone 0.5 mg in 1 g - risk summary there are no data regarding the excretion of betamethasone dipropionate in breast milk, the effects on the breastfed infant, or the effects on milk production after topical application of betamethasone dipropionate cream (augmented) to women who are breastfeeding. it is possible that topical administration of large amounts of betamethasone dipropionate could result in sufficient systemic absorption to produce detectable quantities in human milk. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for betamethasone dipropionate cream (augmented) and any potential adverse effects on the breastfed infant from betamethasone dipropionate cream (augmented) or from the underlying maternal condition. clinical considerations to minimize potential exposure to the breastfed infant via breast milk, use betamethasone dipropionate cream (augmented) on the smallest area of skin and for the shortest duration possible while breastfeeding. advise breastfeeding women not to apply betamethasone dipropionate cream (augmented) directly to the nipple and areola to avoid direct infant exposure [see use in specific populations ( error! hyperlink reference not valid. )] .